| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701937 | Journal of Thoracic Oncology | 2017 | 39 Pages |
Abstract
Trametinib-plus-chemotherapy combinations were tolerable. Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS-mutated NSCLC and meeting prespecified criteria was observed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
David R. MD, Natasha MD, Jean-Pierre MD, PhD, Fabrice MD, PhD, Jaafar MD, PhD, Gerald MD, PhD, Jeffrey R. MD, Karen L. MD, Karen MD, Frances A. MD, Julien MD, PhD, Filip MD, PhD, Olivia S. PhD, Bijoyesh MD, Yuehui PhD, Donna S. PhD, Dan BS, Vijay MD,